Zenesta 1 Tablet SR is a fixed-dose combination medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which enhances glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, leading to a reduction in postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release forms. Zenesta 1 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or dual therapy. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis, severe renal dysfunction, or hypersensitivity to any component. Regular follow-up with healthcare providers is recommended to optimize treatment outcomes and minimize adverse effects.